Drugs of Abuse Testing Products Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Drugs of Abuse Testing Products Market is segmented By Product Type (Analyzers, Rapid Testing Devices, Consumables), By Sample Type (Saliva, Urine, Blood, Others), By End User (Hospitals, Diagnostic Laboratories, Forensic Laboratories, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Drugs of Abuse Testing Products Market Overview

The global drugs-of-abuse testing products market size is estimated to reach at a high CAGR during the forecast period 2023-2030

Drug abuse testing detects one or more illegal substances in the urine, blood, saliva, hair, or sweat not normally found in the body, except for some hormones and steroids measured as part of sports testing.

Drugs of Abuse Testing Products Market Scope

To Know More Insights - Download Sample

Drugs of Abuse Testing Products Market Dynamics

Advances in the non-targeted analysis method for drug abuse testing are expected to drive the market's growth.

Substance abuse negatively impacts all facets of society. Drug testing programs have been developed in many jurisdictions to service law enforcement agencies for drug intelligence, criminal justice systems for the prosecution of drug-related crimes, and the health industry for harm minimization. The significant advancement in the non-targeted analysis is the development of activity-based assays such as the one for the detection of synthetic cannabinoid receptor agonists (SCRAs) based on interactions of the compounds with CB1 and CB2 receptors. Availability of such method can potentially use to screen biofluids for SCRAs without the chemical structural information. The assay can also be used to evaluate the "intrinsic potency" of SCRA formulations, as demonstrated by who synthesized enantiospecifically 4 indazole-3-carboxamide-type SCRA for aiding their detection in seized drug samples. Thus, the advances in the non-targeted analysis method for drug abuse testing are expected to drive the market's growth.

Challenges for detecting the use of many new psychoactive substances (NPS) are expected to hamper the market's growth.

The challenge of detecting the use of a large number of NPS available in the illegal drug market is the limited understanding of their biotransformation following consumption. Many NPS such as SCRAs undergo an extensive metabolic transformation in the body, and drug monitoring needs to target the parent drugs and their metabolites. Studying the metabolism of these compounds is also important to better understand the toxicity of NPS as many NPS metabolites are also pharmacologically active and contribute to the overall toxicity of the parent drugs. Thus, from the above statements, the market is expected to hamper in the forecast period.

Drugs of Abuse Testing Products Market Industry Analysis

PESTAnalysis:   

COVID-19 Impact Analysis

The pandemic caused by the SARS-CoV-2 virus led to a near-worldwide lockdown and positively impacted the drugs-of-abuse testing products. During the pandemic, forced isolation and quarantine have impacted the behavior of drug abusers. Moreover, due to the stringent lockdown measures and social distancing to battle the coronavirus spread, an increase in alcohol and drug abuse is anticipated, further driving to isolated overdosing and acting as a surprising challenge for drug addicts. For instance, according to the Centers for Disease Control and Prevention (CDC), 2021, a person with substance use disorder is expected to be severely ill if infected with the SARS-CoV2 virus. Therefore, there is an increased need for healthcare and public health organizations to be involved in drug abuse testing during the pandemic to minimize the unfavorable health outcomes among the majority of the global population. Thus, it is expected to be positively impacted during the pandemic.

Drugs of Abuse Testing Products Market Segment Analysis

Urine segment is expected to hold the largest market share in this market segment.

The urine segment is estimated for the largest market share in 2020. The segment growth is attributed to the rising number of clinical laboratories associated with medical centers, technological developments in drug abuse testing, increasing number of deaths due to drug overdose, and the growing demand for drug tests are some of the factors which are expected to boost the market in the forecast period. For instance, according to the National Center for Health Statistics, Inappropriate use of opioids is accountable for nearly three-quarters of all drug overdose deaths. It increased from 50,963 in 2019 to an estimated 69,710 in 2020. The majority of opioid deaths resulted from synthetic opioids such as fentanyl, followed by psychostimulants such as methamphetamine. Deaths from cocaine and natural and semi-synthetic opioids, such as prescription pain medicine, also grew in 2020.

Moreover, Vermont saw the biggest percentage rise, with overdose deaths rising by more than 57 percent year over year. Kentucky, South Carolina, West Virginia, and Louisiana are among the states that have seen considerable increases. California had the most drug overdose deaths in raw numbers, with an estimated 9,538, followed by Florida, Pennsylvania, Ohio, and Texas. South Dakota had the fewest fatalities. Additionally, according to the Journal of Applied Laboratory Medicine, 2020, there has been an improved adoption in the targeted panel of urine drug testing. The value of clinical urine drug testing was observed to have developed by providing laboratory-based results interpretation and consultative services.

Drugs of Abuse Testing Products Market Geographical Share

North America region holds the largest market share in the global drugs-of-abuse testing products market.

In 2020, North America had the highest revenue share. The rise in abuse drug use, high rate of adoption of technologically improved devices for drug abuse testing, and growing demand for illegal drugs are all factors contributing to the region's growth, which is likely to continue in the forecast period. For instance, according to the National Survey on Drug Use and Health (NSDUH), conducted annually by the Substance Abuse and Mental Health Services Administration (SAMHSA), 13% of people in the U.S. aged 12 and overused any illicit drug, and in the United States, the two most commonly used illicit drugs are marijuana and opioids. Marijuana is a commonly used illegal drug in the U.S. and the second most commonly used psychoactive drug. The 2019 NSDUH showed that more than 12 million young adults (ages 18 to 25) used marijuana.

Moreover, the United States is grappling with one of its worst-ever drug crises. More than 1,300 people per week die from opioid-related overdoses, a toll that has spiked across the country amid the COVID-19 pandemic. Meanwhile, millions more Americans suffer from opioid addiction. Therefore, it has increased the demand for drugs-of-abuse testing products. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Drugs of Abuse Testing Products Market Companies

The drugs-of-abuse testing products market is vast with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include HWTAi BioTec, Bio Group Medical System S.r.l., LabCorp, Drägerwerk AG & Co. KGaA, Abbott Laboratories, Danaher Corporation (Beckman Coulter, Inc.), BIOSYNEX, Firstep Bioresearch, Inc., Diagnosis, Ameritek, Inc. and Easy Healthcare. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the drugs-of-abuse testing products market globally.

Drugs-of-abuse Testing Products Market Key Companies to Watch

HWTAi BioTec:

Overview:

HWTAI is a manufacturer and a supplier of Medical Consumables based in China. The company is committed to providing innovative and reliable medical products to institutions about One-Stop-Service both in China and internationally. Moreover, the company has 15 years of experience in service with 3000 Clients+ and 40 countries in the past. The products are distributed between the EU and the USA.

Product Portfolio:

HWTAi BioTec is manufacturing drugs-of-abuse testing products, including Rapid drug abuse test DAM-102, DTH-102, DBZ-102, DBA-102 and others.